Irogue Igbinosa, MD, is a Maternal-Fetal Medicine physician at Stanford University. She is currently an NIH Women's Reproductive Health Scholar (K12), and her research focus includes iron deficiency anemia in pregnancy, severe maternal morbidity and mortality, and health equity.

She graduated from the University of Houston and earned her medical degree at Baylor College of Medicine. She subsequently completed her residency in Obstetrics and Gynecology Residency at Louisiana State University School of Medicine Baton Rouge. After residency, she was an AAMC-CDC Public Health Policy Fellow able to serve in the CDC Emergency Operations Center and contribute to research for healthcare providers regarding the management of the Zika virus in pregnant persons. She completed her Maternal Fetal Medicine fellowship at Stanford in 2022.

Dr. Igbinosa is passionate about community-engaged approaches to bridge gaps in evidence-based care for birthing communities and collaborates with local and national policy committees to raise awareness for reproductive justice in maternal health. Her motto is to listen first and serve with compassion.

Clinical Focus

  • Maternal and Fetal Medicine

Professional Education

  • Fellowship: Stanford University Maternal Fetal Medicine Fellowship (2022) CA
  • Board Certification: American Board of Obstetrics and Gynecology, Obstetrics and Gynecology (2021)
  • Internship: Baylor College of Medicine (2011) TX
  • Medical Education: Baylor College of Medicine (2010) TX
  • Residency: Louisiana State University (2015) LA

All Publications

  • Disparities in Maternal and Infant Outcomes. Neurology Langer-Gould, A., Igbinosa, I. I. 2024; 102 (4): e209207

    View details for DOI 10.1212/WNL.0000000000209207

    View details for PubMedID 38261992

  • Racial and Ethnic Disparities in Anemia and Severe Maternal Morbidity. Obstetrics and gynecology Igbinosa, I. I., Leonard, S. A., Noelette, F., Davies-Balch, S., Carmichael, S. L., Main, E., Lyell, D. J. 2023


    To evaluate antepartum anemia prevalence by race and ethnicity, to assess whether such differences contribute to severe maternal morbidity (SMM), and to estimate the contribution of antepartum anemia to SMM and nontransfusion SMM by race and ethnicity.We conducted a population-based cohort study using linked vital record and birth hospitalization data for singleton births at or after 20 weeks of gestation in California from 2011 through 2020. Pregnant patients with hereditary anemias, out-of-hospital births, unlinked records, and missing variables of interest were excluded. Antepartum anemia prevalence and trends were estimated by race and ethnicity. Centers for Disease Control and Prevention criteria were used for SMM and nontransfusion SMM indicators. Multivariable logistic regression modeling was used to estimate risk ratios (RRs) for SMM and nontransfusion SMM by race and ethnicity after sequential adjustment for social determinants, parity, obstetric comorbidities, delivery, and antepartum anemia. Population attributable risk percentages were calculated to assess the contribution of antepartum anemia to SMM and nontransfusion SMM by race and ethnicity.In total, 3,863,594 births in California were included. In 2020, Black pregnant patients had the highest incidence of antepartum anemia (21.5%), followed by Pacific Islander (18.2%), American Indian-Alaska Native (14.1%), multiracial (14.0%), Hispanic (12.6%), Asian (10.6%), and White pregnant patients (9.6%). From 2011 to 2020, the prevalence of anemia increased more than100% among Black patients, and there was a persistent gap in prevalence among Black compared with White patients. Compared with White patients, the adjusted risk for SMM was high among most racial and ethnic groups; adjustment for anemia after sequential modeling for known confounders decreased SMM risk most for Black pregnant patients (approximated RR 1.47, 95% CI 1.42-1.53 to approximated RR 1.27, 95% CI 1.22-1.37). Compared with White patients, the full adjusted nontransfusion SMM risk remained high for most groups except Hispanic and multiracial patients. Within each racial and ethnic group, the population attributable risk percentage for antepartum anemia and SMM was highest for multiracial patients (21.4%, 95% CI 17.5-25.0%), followed by Black (20.9%, 95% CI 18.1-23.4%) and Hispanic (20.9%, 95% CI 19.9-22.1%) patients. The nontransfusion SMM population attributable risk percentages for Asian, Black, and White pregnant patients were less than 8%.Antepartum anemia, most prevalent among Black pregnant patients, contributed to disparities in SMM by race and ethnicity. Nearly one in five to six SMM cases among Black, Hispanic, American Indian-Alaska Native, Pacific Islander, and multiracial pregnant patients is attributable in part to antepartum anemia.

    View details for DOI 10.1097/AOG.0000000000005325

    View details for PubMedID 37678935

  • Hospital intrapartum practices and disparities in severe maternal and neonatal morbidity Leonard, S. A., Xu, X., Davies-Balch, S., Main, E., Bateman, B. T., Rehkopf, D., Lee, H. C., Illuzzi, J., Igbinosa, I., Iwekaogwu, I., Lyell, D. J. MOSBY-ELSEVIER. 2023: S233
  • Iron deficiency anemia in pregnancy. Current opinion in obstetrics & gynecology Igbinosa, I., Berube, C., Lyell, D. J. 2022; 34 (2): 69-76


    PURPOSE OF REVIEW: Anemia in pregnancy is associated with increased maternal and neonatal morbidity. There is increasing awareness amongst obstetricians about the need to screen for iron deficiency anemia (IDA), as well as growing literature on diagnosis and treatment. This review aims to summarize causes, consequences, treatment, and evaluation of IDA in pregnancy.RECENT FINDINGS: National guidelines provide varying guidance on diagnosis and treatment of IDA in pregnancy. Serum ferritin is a helpful adjunct for the diagnosis of IDA. Oral iron remains an option for treatment; absorption is improved with every other day dosing and is effective for patients able to tolerate. Emerging studies on modern generations of intravenous (IV) iron demonstrate shorter infusion times and improved safety profiles. Notably, recent UK guidelines provide consideration for universal IV iron supplementation for treatment of anemia beyond 34 weeks of pregnancy.SUMMARY: Iron, in dietary, oral, and IV forms, has been found effective in resolving anemia in pregnancy. Pregnant people with IDA in the third trimester are more likely to benefit from IV iron. Future studies designed and powered to assess maternal and perinatal morbidity indicators and blood transfusion rates can strengthen recommendations.

    View details for DOI 10.1097/GCO.0000000000000772

    View details for PubMedID 35230991

  • Health Disparities in Antepartum Anemia: The Intersection of Race and Social Determinants of Health Igbinosa, I., Leonard, S. A., Noelette, F., Mujahid, M., Main, E. K., Lyell, D. J. MOSBY-ELSEVIER. 2022: S529-S530
  • Editorial: How COVID-19 has affected maternal-fetal medicine and obstetrics? Current opinion in obstetrics & gynecology Igbinosa, I., Lyell, D. J. 2021; 33 (5): 416-418

    View details for DOI 10.1097/GCO.0000000000000741

    View details for PubMedID 34459793

  • Inflammatory bowel disease and the impact on rates of chorioamnionitis, sepsis, and severe maternal morbidity Igbinosa, I., Trepman, P., Sie, L., Leonard, S. A., Herrero, T. MOSBY-ELSEVIER. 2021: S441–S442
  • Use of Remdesivir for Pregnant Patients with Severe Novel 2019 Coronavirus Disease. American journal of obstetrics and gynecology Igbinosa, I., Miller, S., Bianco, K., Nelson, J., Kappagoda, S., Blackburn, B. G., Grant, P., Subramanian, A., Lyell, D., El-Sayed, Y., Aziz, N. 2020

    View details for DOI 10.1016/j.ajog.2020.08.001

    View details for PubMedID 32771381

  • The obstetric research landscape: a cross-sectional analysis of clinical trials from 2007-2020. American journal of obstetrics & gynecology MFM Steinberg, J. R., Weeks, B. T., Reyes, G. A., Conway Fitzgerald, A. n., Zhang, W. Y., Lindsay, S. E., Anderson, J. N., Chan, K. n., Richardson, M. T., Magnani, C. J., Igbinosa, I. n., Girsen, A. n., El-Sayed, Y. Y., Turner, B. E., Lyell, D. J. 2020: 100253


    Obstetric complications impact over a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetric clinical trial landscape, how it compares to other fields, or factors associated with the successful completion of obstetric trials.To characterize obstetric clinical trials registered on with the primary objective of identifying features associated with early discontinuation and results reporting.This is a cross-sectional study with descriptive, logistic regression and cox regression analyses of clinical trials registered on Our primary exposure variables were trial focus (obstetric or non-obstetric) and trial funding (industry, United States government or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with two primary outcomes: early discontinuation and results reporting.We downloaded data for all studies (n=332,417) registered on from October 1, 2007 to March 9, 2020 from the Aggregate Analysis of the database. We excluded studies with a non-interventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). 4,276 (1.9%) obstetric trials (i.e. interventional studies), and 219,235 (98.1%) non-obstetric trials were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetric trials increased over time (10.8% annual growth rate). Compared to non-obstetric trials, obstetric trials had a greater risk of early discontinuation (adjusted hazard ratio 1.40, 95% confidence interval: 1.21 to 1.62, p<0.0001) and similar odds of results reporting (adjusted odds ratio 0.89, 95% confidence interval: 0.72 to 1.10, p=0.19). Among obstetric trials funders after controlling for confounding variables, United States government-funded trials were at lowest risk of early discontinuation (US government adjusted hazard ratio 0.23, 95% confidence interval 0.07 to 0.69, p=0.009, industry reference; academic adjusted hazard ratio 1.04, 95% confidence interval 0.62 to 1.74, p=0.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions adjusted odds ratio 0.39, 95% confidence interval 0.22 to 0.68, p=0.0009; industry reference; US government adjusted odds ratio 1.06 95% confidence interval 0.53 to 2.09, p=0.87).Obstetric trials represent only 1.9% of all clinical trials in and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetric trials and improving their completion and dissemination to ensure clinical research reflects the obstetric burden of disease and advances maternal health.

    View details for DOI 10.1016/j.ajogmf.2020.100253

    View details for PubMedID 33043288

    View details for PubMedCentralID PMC7537600

  • Relationships of uterine fibroids to racial/ethnic disparities in severe maternal morbidity Igbinosa, I., Leonard, S. A., El-Sayed, Y. Y., Lyell, D. J. MOSBY-ELSEVIER. 2020: S170–S171
  • Early discontinuation and results reporting in obstetric clinical trials: An analysis of 3317 investigations Weeks, B., Steinberg, J. R., Turner, B., Reyes, G., Conway, A. A., Zhang, W. Y., Lindsay, S., Anderson, J. N., Chan, K., Igbinosa, I., Girsen, A., El-Sayed, Y. Y., Lyell, D. J. MOSBY-ELSEVIER. 2020: S55–S56
  • The obstetric clinical trial landscape: a characterization of investigations from 2007-2018 Steinberg, J. R., Weeks, B., Turner, B., Reyes, G., Conway, A. A., Zhang, W. Y., Lindsay, S., Anderson, J. N., Chan, K., Igbinosa, I., Girsen, A., El-Sayed, Y. Y., Lyell, D. J. MOSBY-ELSEVIER. 2020: S459–S460
  • Antepartum anemia and racial/ethnic disparities in blood transfusion in california Igbinosa, I., Leonard, S. A., Butwick, A. J., Lyell, D. J. MOSBY-ELSEVIER. 2020: S304